Media Contact: Lissa Pavluk media@apellis.com (617) 977-6764
- November 4, 2021 Apellis to Present New Data Reinforcing EMPAVELI™ (pegcetacoplan) Efficacy and Safety in Patients with PNH at the 2021 ASH Annual Meeting
- November 3, 2021 Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
- November 1, 2021 Apellis Pharmaceuticals to Host Conference Call on November 8, 2021 to Discuss Third Quarter 2021 Financial Results
- October 15, 2021 Apellis and Sobi Receive Positive CHMP Opinion for Aspaveli® (pegcetacoplan) for the Treatment of PNH
- September 30, 2021 Apellis Announces Detailed Results from Phase 3 DERBY and OAKS Studies Presented at Retina Society Annual Meeting
- September 20, 2021 Apellis Pharmaceuticals to Present at the 2021 Cantor Virtual Global Healthcare Conference
- September 9, 2021 Apellis Announces Top-Line Results from Phase 3 DERBY and OAKS Studies in Geographic Atrophy (GA) and Plans to Submit NDA to FDA in the First Half of 2022
- August 9, 2021 Apellis Pharmaceuticals Reports Second Quarter 2021 Financial Results
- July 29, 2021 Apellis Pharmaceuticals to Host Conference Call on August 9, 2021 to Discuss Second Quarter 2021 Financial Results
- July 26, 2021 Apellis Announces Closing of Previously Announced Exchanges of Approximately $201.1 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock
Displaying 121 - 130 of 279